931 / 1983
How to combine…
chemotherapy and RT
Study
Type of
study
n. pts Inclusion
criteria
RT (Gy)
Type of CT Main Results
SWOG
9024
Phase II 30
T3 +, N0 45 + 25.2 Daily 5-FU 13/30: PSA < 1.0 ng/dL
6/13 negative post-
treatment biopsy
Khil et al Phase II 65
cT2b-c +
GS 9-10,
cT3, or
cTxN1M0
45 + 20-25 Estramustine
Phosphate +
Vinblastine
undetectable PSA at
nadir: 86%
biochemical remission:
48%
MSKCC Phase II 27
High risk
and/or N+
75.6
Estramustine
Phosphate +
Vinblastine
5-y BRFS: 34%
Acute G3 GI tox: 35%
Acute G3 GI tox: 48%
Khil et al Phase II 50
IR-HR 70.2
Docetaxel
Median FUP 54 m
5-y bRFS = 66%
5-y OS = 92%